While further observational studies and large clinical trials with long-term follow-up are needed to fully evaluate the efficiency of the use of this adipokine, leptin could be used as an interesting biomarker in the diagnosis and follow-up of NAFLD, including the combination of leptin level measurement together with metabolic analyses, lipid profile, and glucose levels. This evidence concerns the gene LEP and metabolic dysfunction-associated steatotic liver disease.